Highland Peak Capital LLC Increases Holdings in Grifols, S.A. (NASDAQ:GRFS)

Key Points

• Highland Peak Capital LLC increased its stake in Grifols, S.A. by 24.1%, now owning approximately 5.1% of the company's stock valued at $6.9 million, making it their 7th largest holding.
• Recent analyst coverage includes a downgrade by Deutsche Bank to a "hold" rating, while Wall Street Zen upgraded Grifols to a "strong-buy," with a consensus price target set at $10.30.
• Grifols is set to pay a dividend of $0.1404 per share on August 20th, with an ex-dividend date on August 12th.

Highland Peak Capital LLC grew its holdings in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 24.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 975,835 shares of the biotechnology company's stock after buying an additional 189,625 shares during the period. Grifols accounts for about 5.1% of Highland Peak Capital LLC's portfolio, making the stock its 7th biggest holding. Highland Peak Capital LLC owned approximately 0.14% of Grifols worth $6,938,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new stake in Grifols during the fourth quarter worth approximately $14,434,000. Sequoia Financial Advisors LLC lifted its holdings in Grifols by 14.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 3,399 shares during the last quarter. LPL Financial LLC lifted its holdings in Grifols by 25.0% during the 4th quarter. LPL Financial LLC now owns 75,398 shares of the biotechnology company's stock worth $561,000 after purchasing an additional 15,067 shares during the last quarter. First Trust Advisors LP bought a new stake in Grifols in the 4th quarter valued at $75,000. Finally, GAMMA Investing LLC grew its holdings in Grifols by 426.1% in the 1st quarter. GAMMA Investing LLC now owns 26,087 shares of the biotechnology company's stock valued at $1,850,000 after buying an additional 21,128 shares in the last quarter.

Wall Street Analyst Weigh In

GRFS has been the subject of a number of research reports. Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th. JPMorgan Chase & Co. lifted their price objective on shares of Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research note on Tuesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Grifols in a report on Tuesday. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $10.30.

Grifols Price Performance

NASDAQ GRFS traded up $0.17 during midday trading on Thursday, hitting $10.65. The company had a trading volume of 1,036,109 shares, compared to its average volume of 1,324,246. The company has a market capitalization of $7.32 billion, a PE ratio of 9.10, a P/E/G ratio of 0.36 and a beta of 0.56. Grifols, S.A. has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a current ratio of 2.64, a quick ratio of 0.95 and a debt-to-equity ratio of 1.20. The firm has a 50-day moving average price of $9.39 and a 200-day moving average price of $8.12.

Grifols Announces Dividend

The company also recently disclosed a -- dividend, which will be paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th will be given a dividend of $0.1404 per share. The ex-dividend date of this dividend is Tuesday, August 12th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.